↓ Skip to Main Content
Thasso

Thasso

the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Log in | Register

Main Navigation

  • englishenglish
    • englishenglish
    • françaisfrançais
    • deutschdeutsch
    • italianoitaliano
    • españolespañol
    • portuguêsportuguês
  • thasso
  • thasso: post
  • thasso: communities
    • thasso: community
    • thasso: patient groups
    • thasso: forum
    • thasso: video chat
    • thasso: simple chat
    • thasso: online meetings (ZOOM)
  • thasso: resources
    • theragenomics: useful links
    • theragenomics: survey at thasso
      • survey participants
    • theragenomics: biomarkers
    • theragenomics: companion tests
    • theragenomics: drug labels with annotated information
    • theragenomics: targeted therapies
    • theragenomics: drugs and genes
    • theragenomics: the world of alleles
    • theragenomics: allele-related guideline information
    • theragenomics: videos
    • drugs: interactions
    • drugs: general information
    • drugs: adverse reactions
    • drugs: risk evaluation and mitigation strategies (REMS)
  • thasso: academy
    • health authorities
      • European Medicines Agency (EMA)
      • American Food & Drug Administration (FDA)
      • Swissmedic
      • FDA Ghana
      • NAFDAC Nigeria
      • CDSCO India
      • The Medicines Control Council (MCC), South Africa
      • China Food & Drug Administration (CFDA)
      • Health Canada
    • public domain
      • Clinical Pharmacogenetics Implementation Consortium
      • ACMG Genetic Test Fact Sheets
      • Public Health Genomics Knowledge Base
      • The Human Diagnosis Project
      • Phenotypes And Genotypes Database
      • Genetic Alliance UK
      • Genetics Generation
      • Front Line Genomics
      • Alliance for Cancer Gene Therapy (ACGT)
      • EUPATI The European Patients’ Academy on Therapeutic Innovation
      • European Patient Forum
      • Uppsala Monitoring Center
      • World Health Organisation (WHO)
      • von Hippel Lindau Syndrome (VHL)
      • Cerebral Palsy Symptoms
      • Mesothelioma Fund
      • Multiple Myeloma Research Foundation
      • Open Source Pharma (OSP, Medicine for All)
    • theragenomics worldwide
      • The Human Heredity and Health in Africa (H3Africa)
      • The Asia Cohort Consortium
      • GenomeAsia 100K
    • patient & consumer health
      • ThinkGenetic
      • Consumer Health Labs
      • Exercise & Heart Disease
      • UCSF: Eating right for your heart
      • Hormones Matter
      • Living with Arthritis
      • Living with Cannabis
      • Yum of China (Foods)
    • digital therapeutics in theragenomic medicine
      • Digital Therapeutics Alliance (DTA)
      • Digital Health Alliance
    • miscellaneous
      • Partners Health Care / Personalized Medicine
      • Worst Pills / Best Pills
      • Pharmagenomics Research Network
      • Mayo Clinic: Personalized Medicine
      • Patient Power
      • Patient Opinion (UK)
      • Drug Injury Watch (Tom Lamb)
      • Ways To Fund Cancer Treatments
      • MedScape India
      • Swiss Academy of Medical Sciences
      • IDICAP: An Integrated Drug Intervention for Cancer Panel
      • PanDrugs
      • Soccer Genomics
    • companies
      • Moderna
      • BionTech
      • FDNA (Face2Gene Home)
      • IONIS Pharmaceuticals
      • Boehringer Ingelheim Home
      • Bristol-Myers Squipp Home
      • Glaxo Home
      • Novartis Home
      • Roche Home
      • AstraZeneca Home
      • Merck Home
      • Gilead Home
      • Takeda Home
      • Janssen Home
      • Novo Nordisk Home
      • Amgen Home
    • products
      • Axicabtagene ciloleucel (Yescarta)
      • Ledipasvir/Sofosbuvir (Harvoni)
      • Sofosbuvir (Sovaldi)
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Sekukinumab (Cosentyx)
      • Rivaroxaban (Xarelto)
      • Valsartan/Amlodipin/HCT (Exforge/HCT)
      • Aripiprazole (Abilify)
      • Rosuvastatin (Crestor)
      • Flibanserin (Addyi)
      • Onasemnogene abeparvovec-xioi (Zolgensma)
      • Voretigene neparvovec (Luxturna)
  • thasso: about
    • vision
    • background
    • the apomediary patient
    • disclaimers
    • policies
    • contact
  • donations $
  • Cookie Policy (EU)
Home › Posts tagged Sorafenib [Nexavar]

Tag: Sorafenib [Nexavar]

Fatal Adverse Events with Pazopanib [Votrient], Sorafenib [Nexavar], and Sunitinib [Sutent]

By Joseph Gut - thasso Posted on February 12, 2012 Posted in Adverse Drug Reaction [ADR], Thasso Post Tagged with Gastrointestinal Stromal Tumors (GIST), Hemorrhage, Hepatocellular Cancer, Hepatocellular Cancer, Medscape Oncology News, Myocardial Ischemia, Pazopanib [Votrient], Renal Cell Carcinoma, Sorafenib [Nexavar], Sunitinib [Sutent], VEGF Receptor Tyrosine Kinase Inhibitor

February 12, 2012 – From an article published in Medscape Oncology News on February 9, 2012, we learn the following (article in full, all rights resting with Medscape Oncology News): _______________ February 9, 2012— New details on the risk for …

Fatal Adverse Events with Pazopanib [Votrient], Sorafenib [Nexavar], and Sunitinib [Sutent] Read more »

In/Out

  • Log in

Optional: Social Subscribe/Login

thasso: donate

We need your help. Please support the development of thasso through donations. Thank you.    Nous avons besoin de votre aide. S'il vous plaît, vous pouvez soutenir le développement de thasso grâce à des dons. Merci.    Wir brauchen Ihre Hilfe. Bitte unterstützen Sie die Entwicklung von thasso durch Spenden. Vielen Dank.    Abbiamo bisogno del tuo aiuto. Si prega di sostenere lo sviluppo di thasso attraverso donazioni. Grazie.    Nós precisamos da sua ajuda. Por favor, apoie o desenvolvimento de thasso através de doações. Obrigada.     Necesitamos tu ayuda. Por favor apoye el desarrollo de thasso con donaciones. Muchas gracias.

thasso: conditions

thasso: newest tweets

Tweets by thasso_info

 

RSS FDA press releases

  • FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types September 29, 2023
  • FDA Roundup: September 29, 2023 September 29, 2023
  • FDA Launches Pilot Program to Help Further Accelerate Development of Rare Disease Therapies September 29, 2023
  • FDA Proposes Rule Aimed at Helping to Ensure Safety and Effectiveness of Laboratory Developed Tests September 29, 2023
  • FDA Seeks Fines Against 22 Retailers for Selling Illegal Youth-Appealing E-Cigarettes September 28, 2023

RSS FDA MedWatch

  • 2023 Safety Communications September 29, 2023
  • Update: Recommendations for Certain O&M Halyard Surgical N95 Respirators, Surgical Masks, and Pediatric Face Masks: FDA Safety Communication September 29, 2023
  • SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) Due to Potential for Cross Contamination with a Non-Antibacterial ßlactam Drug Substance September 28, 2023
  • VistaPharm LLC Issues Voluntary Nationwide Recall of Sucralfate Oral Suspension, 1g/10mL Due to Microbial Contamination Identified as Bacillus Cereus September 22, 2023
  • Hamilton Medical Inc. Recalls HAMILTON-C1, C2, C3, T1 Ventilators for Software Issues that May Cause Ventilators to Stop Without Notice September 22, 2023

RSS EMA Press releases

  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 September 2023, PRAC, 29/09/2023 September 29, 2023
  • EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep, CHMP, 15/09/2023 September 28, 2023
  • Towards a permanent collaboration framework for EMA and Health Technology Assessment bodies, , 15/09/2023 September 15, 2023
  • Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023, CHMP, 15/09/2023 September 15, 2023
  • EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna, CHMP, 15/09/2023 September 15, 2023

RSS random genetics

  • A new perspective on myositis subgrouping using genetics September 29, 2023
    In a new study from Karolinska Institutet, the researchers found that combining information from blood markers and genetics reveals distinct subgroups of patients with myositis, which may help to improve disease classification and treatment. The study was published in eBioMedicine.
  • A new bioinformatics pipeline solves a 50-year-old blood group puzzle September 29, 2023
    Currently, a lot is known about which genes are responsible for our individual blood groups; however, not much is understood about how and why the levels of the blood group molecules differ between one person and another. This knowledge can be important for blood transfusion safety. Now a research group at Lund University in Sweden […]
  • Researchers take steps toward stopping the 'conversation' between cancerous tumors and nerves September 29, 2023
    Cancer tumors hijack the genetic program used by developing nerves. This is shown in a study published in the journal Frontiers in Genetics by researchers at Umeå University. In the long term, the results may open up new ways of treating cancer by limiting the tumor's interaction with the nerves.
  • Genetic ancestry and social environment may influence how aggressive breast cancer is in Black women September 29, 2023
    For Black women, breast cancer is the most commonly diagnosed cancer, and as of 2019 it has surpassed lung cancer as the leading cause of cancer death in this population, according to the American Cancer Society. Additionally, studies have shown a high prevalence of triple-negative breast cancer (TNBC), an aggressive subtype of breast cancer among […]
  • Researchers find a cancer enhancer in the genome that drives tumor cell growth September 29, 2023
    University of Toronto (U of T) researchers have found that cancer cells can enhance tumor growth by hijacking enhancer DNA normally used when tissues and organs are formed. The mechanism, called enhancer reprogramming, occurs in bladder, uterine, breast and lung cancer, and could cause these types of tumors to grow faster in patients.

Recent Comments

  • Joseph Gut - thasso on Is there living pharmacogenovigilance behind Semaglutide drugs?: “Of course, all the uncertainties about the “safety” of Wegovy (Semaglutid) for individual patients remain the same as those addressed…” Aug 27, 05:10
  • Joseph Gut - thasso on Is there living pharmacogenovigilance behind Semaglutide drugs?: “There seem to be additional indications profiting from Wegovy (Semaglutide). See this very recent article in Medscape: https://www.medscape.com/viewarticle/995844?ecd=wnl_tp10_daily_230825_MSCPEDIT_etid5788179&uac=190401EN&impID=5788179, citing the…” Aug 26, 10:26
  • Joseph Gut - thasso on Ist Semaglutid ein Abnehmwunder?: “Wegovy (Semaglutid) ist mittlerweile auch in Deutschland legal erhältlich. Eine gute Idee ist jedoch weiterhin, es nur unter ärztlicher Anleitung…” Aug 8, 10:16
  • Joseph Gut - thasso on Sind isometrische Übungen die wirksamste Methode um den Blutdruck zu senken?: “Time will tell. Wir werden sehen, ob solche Übungen tatsächlich den Blutdruck (stabil) senken können.Dazu werden noch eine Anzahl Studien…” Jul 31, 22:59
  • Joseph Gut - thasso on Is there pre-emptive genotyping to avoid adverse drug effects (ADRs)?: “Just testing. https://www.alphamannosidosis.com/en/for-patients-caregivers/disease-information/?utm_source=google&utm_medium=cpc&utm_campaign=AlphamannSearch_Paziente2020&gclid=EAIaIQobChMI2Pv7wNaC_AIVWud3Ch1J8AMPEAAYAiAAEgJGI_D_BwE/” Dec 18, 08:50

Tag Cloud

Adverse Drug Reaction (ADR) African American Allelic Variant Allelic Variants American Food & Drug Administration (FDA) American Food & Drug Administration (FDA) Boxed Warning Breast Cancer Canagliflozin (Invokana) Cancer Children Committee for Medicinal Products for Human Use (CHMP) Companion Test Covid-19 Disease Diabetes Drug Induced Liver Injury (DILI) Epidermal Growth Factor Receptor (EGFR) Ethnicity European Medicine Agency (EMA) European Medicines Agency (EMA) Food and Drug Administration (FDA) Gene Therapy Genetic Background Genetic Predisposition Genetic Testing Genotype Health Canada Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab [Keytruda] Personalized Medicine Phenotype Progressive Multifocal Leukoencephalopathy (PML) Rare Disease Risk Evaluation and Mitigation Strategy (REMS) SARS-CoV-2 Schizophrenia Sildenafil [Viagra] Stevens Johnson Syndrome [SJS] Targeted Therapy ThassoBase Thasso Post Theragenomic Medicine Toxic Epidermal Necrolysis (TEN) Type 2 Diabetes Vemurafenib [Zelboraf]

Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
© 2023 Thasso | Powered by Responsive Theme
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}